Comparison of various forms of therapy in two different mouse tumor systems

Clinical versus histological grading in the assessment of cutaneous graft versus host disease.

European journal of medical research·2019

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).

BMC cancer·2017

Donor-Specific Antibodies Are Produced Locally in Ectopic Lymphoid Structures in Cardiac Allografts.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

Plasma levels of alpha-1-antichymotrypsin are elevated in patients with chronic heart failure, but are of limited prognostic value.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2014

Current technologies for HER2 testing in breast cancer.

Critical reviews in oncology/hematology·2011

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.

Leukemia·2010

Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.

Cancer treatment reports·1987

IV melphalan in children.

Cancer treatment reports·1987

Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.

Cancer treatment reports·1987

Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.

Cancer treatment reports·1987

Doxorubicin distribution in human breast cancer.

Cancer treatment reports·1987

Phase I study of echinomycin.

Cancer treatment reports·1987

EGFR kinase inhibitors from novel thiazole derivatives: synthesis, anticolon cancer, docking, and ADME studies.

Future medicinal chemistry·2026

Beyond the ceiling: A critical analysis of microRNA research in cutaneous T-cell lymphoma and a roadmap forward.

The Journal of investigative dermatology·2026

Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia.

Cancer discovery·2026

Epigenetic Repression of Type I Interferon Signaling by RUNX2 Drives Immune Checkpoint Blockade Resistance in Osteosarcoma.

Cancer research·2026

The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity.

Cancer research·2026

Targeting glutaminase (GLS) to suppress CXCL8 secretion and sensitize esophageal squamous cell carcinoma to immunotherapy.

Journal of chemotherapy (Florence, Italy)·2026

Related Experiment Videos

Comparison of various forms of therapy in two different mouse tumor systems

Related Concept Videos

Clinical versus histological grading in the assessment of cutaneous graft versus host disease.

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).

Donor-Specific Antibodies Are Produced Locally in Ectopic Lymphoid Structures in Cardiac Allografts.

Plasma levels of alpha-1-antichymotrypsin are elevated in patients with chronic heart failure, but are of limited prognostic value.

Current technologies for HER2 testing in breast cancer.

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.

Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.

IV melphalan in children.

Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.

Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.

Doxorubicin distribution in human breast cancer.

Phase I study of echinomycin.

EGFR kinase inhibitors from novel thiazole derivatives: synthesis, anticolon cancer, docking, and ADME studies.

Beyond the ceiling: A critical analysis of microRNA research in cutaneous T-cell lymphoma and a roadmap forward.

Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia.

Epigenetic Repression of Type I Interferon Signaling by RUNX2 Drives Immune Checkpoint Blockade Resistance in Osteosarcoma.

The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity.

Targeting glutaminase (GLS) to suppress CXCL8 secretion and sensitize esophageal squamous cell carcinoma to immunotherapy.

Related Experiment Videos

Comparison of various forms of therapy in two different mouse tumor systems

Related Concept Videos

Related Articles